← All trials
NCT05890118
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2023
- Primary completion
- Nov 28, 2023
- Completion date
- Nov 28, 2023
- First posted
- Jun 6, 2023
- Last posted
- Oct 30, 2023
- Enrollment
- 55
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- RANI TherapeuticsLead sponsor
- RANI TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.